• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Black Titan Corporation seeks to explore Long-Term Strategic Crypto Initiatives with potential Strategic Investments in Digital Currencies

    10/6/25 4:15:00 PM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BTTC alert in real time by email

    NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Black Titan Corporation. (NASDAQ:BTTC) (the "Company" or "Black Titan"), today announced plans to seek long-term strategic crypto initiatives with potential strategic investments in digital currencies. Black Titan is exploring the utilization of a digital currency holding strategy to invest in and capitalize on cryptocurrency opportunities. Black Titan is actively exploring additional investments to expand its portfolio through direct coin acquisitions, mining, and fintech-related mergers and acquisitions.

    Chay W. J., CEO of Black Titan, remarked, "The approach of leveraging debt, equity, and cash flow to build Crypto holdings has delivered strong results for numerous companies and their investors. We think a broader strategy should increase investor access to emerging coins with greater growth potential. With the new Trump administration expressing strong optimism and major financial institutions potentially embracing this alternative asset class, it has become clear that now is the opportune moment to make a strategic move into the space."

    Forward-Looking Statements

    This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to our ability to raise capital, the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

    Media & Investor Contacts:

    Chay W. J.

    Chief Executive Officer

    (786) 769-7512



    Get the next $BTTC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BTTC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BTTC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Black Titan Corporation seeks to explore Long-Term Strategic Crypto Initiatives with potential Strategic Investments in Digital Currencies

    NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Black Titan Corporation. (NASDAQ:BTTC) (the "Company" or "Black Titan"), today announced plans to seek long-term strategic crypto initiatives with potential strategic investments in digital currencies. Black Titan is exploring the utilization of a digital currency holding strategy to invest in and capitalize on cryptocurrency opportunities. Black Titan is actively exploring additional investments to expand its portfolio through direct coin acquisitions, mining, and fintech-related mergers and acquisitions. Chay W. J., CEO of Black Titan, remarked, "The approach of leveraging debt, equity, and cash flow to build Crypto holdings has delivered stro

    10/6/25 4:15:00 PM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Titan Pharmaceuticals, Inc. Announces Closing of Merger with Black Titan Corporation

    NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. ("Titan" or "TTNP") today announced the successful closing of its previously announced merger with Black Titan Corporation ("Black Titan") and TalenTec Sdn. Bhd. ("TalenTec"). Following the merger, the combined company's ordinary shares, $0.0001 par value per share, will trade on the Nasdaq stock exchange under the ticker symbol NASDAQ: BTTC. Pursuant to the Merger and Contribution and Share Exchange Agreement dated August 19, 2024, Titan has become a wholly owned subsidiary of Black Titan Corporation, effective as of October 1, 2025. As part of the transaction, each issued and outstanding share of Titan common stock

    10/3/25 5:26:00 PM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BTTC
    SEC Filings

    View All

    SEC Form 425 filed by Black Titan Corporation

    425 - Black Titan Corp (0002034400) (Subject)

    10/3/25 5:26:58 PM ET
    $BTTC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care